Results from Preclinical Studies:
LGM2605 significantly reduced disease progression in non-human primate asthma models
LGM2605 demonstrated safety in multiple rodent toxicology studies
LGM2605 PK/PD data in non-human primates shows good oral bioavailability
LGM2605 shown to rehabilitate donor lungs to be used in transplant
FDA meeting held 2018 to define development under device guidelines
Robust Intellectual Property:
LignaMed holds exclusive licenses to the patents for LGM2605 from The Trustees of the University Of Pennsylvania and The Scripps Institute
Funding Awarded:
Awarded $5.2 million dollar contract from National Institutes of Health to develop LGM2605 as a medical countermeasure agent to treat radiation lung damage from nuclear accident or attack.
Awarded $278,000 phase I STTR grant award from National Institutes of Health to develop LGM2605 as a treatment for asthma.
Awarded $125,000 phase I SBIR grant award from NASA to develop LGM2605 as a mitigator of space radiation–induced vascular damage. This is part of NASA’s space travel to Mars program.
Awarded $755,000 phase II SBIR grant award from NASA to develop LGM2605 as a mitigator of space radiation–induced vascular damage. This is part of NASA’s space travel to Mars program.
Awarded $300,000 phase I STTR grant award from National Institutes of Health to develop LGM2605 for organ preservation.
Awarded $2.6 million dollar fast track phase I /phase II grant award from National Institutes of Health to develop LGM2605 as a device to rehabilitate donor lungs.
Awarded $3 million NIH/NIAID Phase II STTR grant award for Asthma